Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 2Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4OTHER_GOV 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 5

Conditions

Breast Neoplasms 555Lymphoma 447Precursor Cell Lymphoblastic Leukemia-Lymphoma 413Lymphoma, Large B-Cell, Diffuse 348Leukemia 346Multiple Myeloma 336Lymphoma, Non-Hodgkin 317Leukemia, Myeloid, Acute 289Leukemia, Lymphocytic, Chronic, B-Cell 286Lymphoma, Follicular 241Burkitt Lymphoma 217Myelodysplastic Syndromes 211Lymphoma, Mantle-Cell 202Hodgkin Disease 193Recurrence 153Lymphoma, B-Cell, Marginal Zone 142Melanoma 135Lymphoma, Large-Cell, Immunoblastic 116Neoplasms 109Lymphoma, B-Cell 103Neuroblastoma 101Neoplasms, Plasma Cell 99Triple Negative Breast Neoplasms 94Ovarian Neoplasms 94Leukemia, Myelogenous, Chronic, BCR-ABL Positive 91Myeloproliferative Disorders 87Hematologic Neoplasms 87Leukemia, Myeloid, Chronic-Phase 83Leukemia, Myeloid, Accelerated Phase 80Leukemia, Myelomonocytic, Chronic 78

Interventions

Paclitaxel 15atezolizumab 11Gemcitabine 11Carboplatin 9pembrolizumab 8Docetaxel 8Bevacizumab 8Irinotecan 7Injections 6Cetuximab 6Capecitabine 6Sunitinib 5Leucovorin 5Fluorouracil 5Cyclophosphamide 5tocilizumab 4pazopanib 4olaparib 4navitoclax 4liposomal doxorubicin 4Topotecan 4Oxaliplatin 4Nivolumab 4Erlotinib Hydrochloride 4temsirolimus 3spartalizumab 3lenvatinib 3fludarabine 3cobimetinib 3Cisplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Solid Tumors × Cyclophosphamide × Clear all
NCT06066424 2026-05-15

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

M.D. Anderson Cancer Center

Phase 1 Recruiting
54 enrolled
Other solid neoplasm

Solid Tumors

NCT02498912 2025-07-31

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
18 enrolled
Other solid neoplasm

Solid Tumors

NCT05648994 2022-12-13

TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors

Fujian Cancer Hospital

Phase EARLY_PHASE1 Unknown
30 enrolled
Other solid neoplasm

Solid Tumors

NCT00586560 2012-05-15

KTN10010

Baylor College of Medicine

Phase 1 Completed
15 enrolled
Other solid neoplasm

Solid Tumors

NCT00628732 2009-01-28

A Pharmacokinetic Study of Oral Cyclophosphamide and Topotecan in Children With Recurrent Solid Tumors

Children's Medical Center Dallas

Phase 2 Completed
36 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡